UK-based biotech firm Orchard Therapeutics has been awarded the fast track PRIME Designation from the European regulator for its investigational gene therapy OTL-300.
The lentiviral gene therapy is being developed as a possible treatment for transfusion-dependent beta-thalassemia (TDBT), the most severe form of beta-thalassemia.
Orchard picked up the therapy earlier this year from GlaxoSmithKline (LSE: GSK), as part of a deal which saw GSK transfer its portfolio of approved and investigational rare disease gene therapies. GSK took a near-20% stake in the firm, and a seat on the board.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze